Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children...

Area of Science:

• Pediatric Hematology
• Pharmacokinetics and Pharmacodynamics
• Sickle Cell Disease Therapeutics

Background:

• Hydroxyurea is FDA-approved for pediatric sickle cell anemia (SCA), but traditional dosing strategies show high variability in patient response.
• Standard weight-based hydroxyurea dosing to reach maximum tolerated dose (MTD) can take 6-12 months, delaying clinical benefits.
• Individualized pharmacokinetic (PK) profiles are crucial for optimizing hydroxyurea therapy in children with SCA.

Purpose of the Study:

• To prospectively validate a novel personalized, PK-guided hydroxyurea dosing strategy in pediatric patients with SCA.
• To evaluate the primary endpoint of time to reach the maximum tolerated dose (MTD) using the novel strategy.
• To assess the safety and efficacy, including laboratory responses, of PK-guided hydroxyurea dosing compared to traditional methods.

Main Methods:

• The Therapeutic Response Evaluation and Adherence Trial (TREAT) enrolled 50 children with SCA, starting hydroxyurea at a median age of 11 months.
• A single oral 20 mg/kg dose of hydroxyurea was administered, followed by sparse PK sampling (3 samples over 3 hours).
• Individual PK data were analyzed using a population PK model to determine a personalized starting dose targeting the MTD.

Main Results:

• The PK-guided hydroxyurea dosing strategy significantly reduced the time to MTD, achieving it in a median of 4.8 months (IQR 3.3-9.3), compared to 6-12 months historically (p < 0.0001).
• PK-guided dosing resulted in robust laboratory responses, with higher mean hemoglobin (10.1 ± 1.3 g/dL) and HbF (33.3 ± 9.1%) levels compared to traditional dosing.
• The higher PK-guided starting doses (27.7 ± 4.9 mg/kg/d) were safe, with no excess hematologic toxicities observed.

Conclusions:

• A personalized, PK-guided hydroxyurea dosing strategy is effective in accelerating the time to MTD for children with SCA.
• This approach leads to superior and faster laboratory responses, including increased hemoglobin and HbF levels, compared to traditional dosing.
• Early initiation of hydroxyurea with personalized dosing offers significant clinical benefits for pediatric SCA patients, surpassing historical outcomes.